Evaluation of Bevacizumab effect on diabetic macular edema in diabetic patients .

Evaluation of the changes in the OCT angiography after the Intra Vitreal Injection of Bevacizumab in diabetic Patients with Clinically Significant Macular Edema.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190518043622N1

Enrollment

Registered

2020-09-04

Start date

2018-06-04

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema. Diabetic retinopathy

Interventions

Intervention group: ?Intravitreal injection of 1.25 mg of Bevacizumab(or stivant) will be performed by other expert in operation room under sterile condition ( for patients with diabetic macular ede

Eligibility

Sex/Gender

All

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with diabetic macular edema age between 30-75 years old Central macular thickness more than 300 microne based on OCT measurement

Exclusion criteria

Exclusion criteria: Myopia more than 6 diopters other macular diseases like macular hole and CNV Some drugs :Hydroxycloroquine consumption Previous history of chemotherapy and radiotherapy History of vitrectomy

Design outcomes

Primary

Measure	Time frame
Change in macular thickness. Timepoint: Before intervention and 1 month after intervention. Method of measurement: Evaluation of macular thickness with OCT angiography.;Change in geometrical feature of FAZ area. Timepoint: Before intervention and 1 month after intervention. Method of measurement: Evaluation of geometrical features of macula with OCT angiography and analyzing it with MATLAB.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArash Ghazanfari

Shiraz University of Medical Sciences

Arash.ghazanfari@yahoo.com+98 71 3633 3615

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026